Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in neurogenic detrusor overactivity with neurological respiratory impairment
NL-OMON31185Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in detrusor hyperreflexia (DH) and urinary incontinence (UI) (3 arms), sponsored by Allergan. Primary endpoints: Forced Vital Capacity, Forced Expiratory Volume in 1 second and 3 more. Planned start Aug 2007; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)urinary incontinence (UI)
Beyond the preview
Go deeper on NL-OMON31185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31185.